Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells

• Published in: Cell cycle (Georgetown, Tex.) Vol. 12; no. 11; pp. 1791 - 1801
• Main Authors: Fiaschi, Tania, Giannoni, Elisa, Taddei, Letizia, Cirri, Paolo, Marini, Alberto, Pintus, Gianfranco, Nativi, Cristina, Richichi, Barbara, Scozzafava, Andrea, Carta, Fabrizio, Torre, Eugenio, Supuran, Claudiu, Chiarugi, Paola
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.06.2013; Landes Bioscience
• Subjects: acidity; Animals; Antigens, Neoplasm - chemistry; Antigens, Neoplasm - genetics; Antigens, Neoplasm - metabolism; cancer-associated fibroblasts; Carbonic Anhydrase IX; Carbonic Anhydrases - chemistry; Carbonic Anhydrases - genetics; Carbonic Anhydrases - metabolism; Cells, Cultured; Epithelial-Mesenchymal Transition; Fibroblasts - cytology; Fibroblasts - metabolism; Humans; Hypoxia-Inducible Factor 1 - metabolism; Male; Matrix Metalloproteinase 2 - metabolism; Matrix Metalloproteinase 9 - chemistry; Matrix Metalloproteinase 9 - genetics; Matrix Metalloproteinase 9 - metabolism; Mice; Mice, SCID; prostate cancer; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; RNA Interference; RNA, Small Interfering - metabolism; Transplantation, Heterologous; Up-Regulation; cancer-associated fibroblasts; prostate cancer; epithelial-mesenchymal transition; acidity; carbonic anhydrase IX
• ISSN: 1538-4101; 1551-4005
• DOI: 10.4161/cc.24902

Extracellular acidification, a mandatory feature of several malignancies, has been mainly correlated with metabolic reprogramming of tumor cells toward Warburg metabolism, as well as to the expression of carbonic anydrases or proton pumps by malignant tumor cells. We report herein that for aggressive prostate carcinoma, acknowledged to be reprogrammed toward an anabolic phenotype and to upload lactate to drive proliferation, extracellular acidification is mainly mediated by stromal cells engaged in a molecular cross-talk circuitry with cancer cells. Indeed, cancer-associated fibroblasts, upon their activation by cancer delivered soluble factors, rapidly express carbonic anhydrase IX (CA IX). While expression of CAIX in cancer cells has already been correlated with poor prognosis in various human tumors, the novelty of our findings is the upregulation of CAIX in stromal cells upon activation. The de novo expression of CA IX, which is not addicted to hypoxic conditions, is driven by redox-based stabilization of hypoxia-inducible factor-1. Extracellular acidification due to carbonic anhydrase IX is mandatory to elicit activation of stromal fibroblasts delivered metalloprotease-2 and -9, driving in cancer cells the epithelial-mesenchymal transition epigenetic program, a key event associated with increased motility, survival and stemness. Both genetic silencing and pharmacological inhibition of CA IX (with sulfonamide/sulfamides potent inhibitors) or metalloprotease-9 are sufficient to impede epithelial-mesenchymal transition and invasiveness of prostate cancer cells induced by contact with cancer-associated fibroblasts. We also confirmed in vivo the upstream hierarchical role of stromal CA IX to drive successful metastatic spread of prostate carcinoma cells. These data include stromal cells, as cancer-associated fibroblasts as ideal targets for carbonic anhydrase IX-directed anticancer therapies.